אינספרה 50 מ"ג - Inspra 50 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||
|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | C03DA Aldosterone antagonists | ||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||
| ×ת×××× | Inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF < or = 40 % ) and clinical evidence of heart failure after recent myocardial infarction.Inspra is indicated in addition to standard optimal therapy, to reduce the risk of cardiovascular morbidity and mortality in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF < or = 30%).
| ||||||
| |||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 Â
| ||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××× ×¡×¤×¨× 50 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | FAREVA AMBOISE, FRANCE |
| ×©× ××¢× ×ר×ש×× | PFIZER PFE PHARMACEUTICALS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 12/2014. ר×ש××× ×ת×ר××: 12/2014 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־17 באוגוסט 2021 ב־10:08